STUDY OF THE EFFECT OF LOMUSTIN ON HER2-POSITIVE BREAST CANCER IN FVB/N HER-2 TRANSGENIC MICE
Because of the high risk of brain metastases from HER2-positive breast cancer, the study of the anticancer activity of drugs used to treat brain tumors, in particular lomustine, is of great importance. In the FVB/N Her-2 transgenic mice bearing HER2-positive breast cancer (BC HER2+), a single oral a...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2019-11-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/1188 |
| _version_ | 1797875822717042688 |
|---|---|
| author | A. N. Stukov S. F. Vershinina N. A. Koziavin T. Yu. Semiglazova L. V. Filatova D. Kh. Latipova A. O. Ivantsov V. G. Bespalov A. L. Semenov O. A. Belyaeva G. S. Kireeva V. A. Alexandrov G. V. Tochilnikov I. N. Vasilyeva M. A. Maydin M. L. Tyndyk S. S. Kruglov G. A. Yanus V. N. Yurova |
| author_facet | A. N. Stukov S. F. Vershinina N. A. Koziavin T. Yu. Semiglazova L. V. Filatova D. Kh. Latipova A. O. Ivantsov V. G. Bespalov A. L. Semenov O. A. Belyaeva G. S. Kireeva V. A. Alexandrov G. V. Tochilnikov I. N. Vasilyeva M. A. Maydin M. L. Tyndyk S. S. Kruglov G. A. Yanus V. N. Yurova |
| author_sort | A. N. Stukov |
| collection | DOAJ |
| description | Because of the high risk of brain metastases from HER2-positive breast cancer, the study of the anticancer activity of drugs used to treat brain tumors, in particular lomustine, is of great importance. In the FVB/N Her-2 transgenic mice bearing HER2-positive breast cancer (BC HER2+), a single oral administration of lomustine at a dose of 50 mg/kg resulted in a significant tumor growth inhibition (up to 96 %, p<0.0001). The tumor growth index (TGI) expressed as a ratio between the areas under the kinetic curves of tumor growth in the study and control groups and amounted to 33 % (p<0.001) indicated the high activity of lomustine. However, the effect of lomustine on intramuscularly transplanted Ehrlich tumor was insignificant (tumor growth inhibition and tumor growth index were <39 % and 68 %, respectively). Lomustine administered orally at a single dose of 50 mg/kg 24 hours after intracranial transplantation of BC HER2+ increased the median survival time up to 30 days in FVB/N mice compared to 21 days in the control group mice (p<0.001). The high therapeutic effect of lomustine in HER2-positive breast cancer mice is likely can be explained by the biological characteristics of this tumor; therefore clinical trials of lomustine for HER2-positive tumors are needed. |
| first_indexed | 2024-04-10T01:53:42Z |
| format | Article |
| id | doaj.art-d4de6c83be42427f8b4c74e1808c76a0 |
| institution | Directory Open Access Journal |
| issn | 1814-4861 2312-3168 |
| language | Russian |
| last_indexed | 2024-04-10T01:53:42Z |
| publishDate | 2019-11-01 |
| publisher | Russian Academy of Sciences, Tomsk National Research Medical Center |
| record_format | Article |
| series | Сибирский онкологический журнал |
| spelling | doaj.art-d4de6c83be42427f8b4c74e1808c76a02023-03-13T09:05:52ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682019-11-01185546010.21294/1814-4861-2019-18-5-54-60672STUDY OF THE EFFECT OF LOMUSTIN ON HER2-POSITIVE BREAST CANCER IN FVB/N HER-2 TRANSGENIC MICEA. N. Stukov0S. F. Vershinina1N. A. Koziavin2T. Yu. Semiglazova3L. V. Filatova4D. Kh. Latipova5A. O. Ivantsov6V. G. Bespalov7A. L. Semenov8O. A. Belyaeva9G. S. Kireeva10V. A. Alexandrov11G. V. Tochilnikov12I. N. Vasilyeva13M. A. Maydin14M. L. Tyndyk15S. S. Kruglov16G. A. Yanus17V. N. Yurova18ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава РоссииФГБУ «Российский научный центр радиологии и хирургических технологий имени академика А.М. Гранова» Минздрава РоссииФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава РоссииФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава РоссииФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава РоссииФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава РоссииФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава РоссииФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава РоссииФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава РоссииФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава РоссииФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава РоссииФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава РоссииФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава РоссииФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава РоссииФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава РоссииФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава РоссииФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава РоссииФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России; ФГБОУ ВО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава РоссииФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава РоссииBecause of the high risk of brain metastases from HER2-positive breast cancer, the study of the anticancer activity of drugs used to treat brain tumors, in particular lomustine, is of great importance. In the FVB/N Her-2 transgenic mice bearing HER2-positive breast cancer (BC HER2+), a single oral administration of lomustine at a dose of 50 mg/kg resulted in a significant tumor growth inhibition (up to 96 %, p<0.0001). The tumor growth index (TGI) expressed as a ratio between the areas under the kinetic curves of tumor growth in the study and control groups and amounted to 33 % (p<0.001) indicated the high activity of lomustine. However, the effect of lomustine on intramuscularly transplanted Ehrlich tumor was insignificant (tumor growth inhibition and tumor growth index were <39 % and 68 %, respectively). Lomustine administered orally at a single dose of 50 mg/kg 24 hours after intracranial transplantation of BC HER2+ increased the median survival time up to 30 days in FVB/N mice compared to 21 days in the control group mice (p<0.001). The high therapeutic effect of lomustine in HER2-positive breast cancer mice is likely can be explained by the biological characteristics of this tumor; therefore clinical trials of lomustine for HER2-positive tumors are needed.https://www.siboncoj.ru/jour/article/view/1188her2-положительный рак молочной железытрансгенные по гену her2 мыши линии fvb/nинтракраниальная опухольломустининдекс роста опухоли |
| spellingShingle | A. N. Stukov S. F. Vershinina N. A. Koziavin T. Yu. Semiglazova L. V. Filatova D. Kh. Latipova A. O. Ivantsov V. G. Bespalov A. L. Semenov O. A. Belyaeva G. S. Kireeva V. A. Alexandrov G. V. Tochilnikov I. N. Vasilyeva M. A. Maydin M. L. Tyndyk S. S. Kruglov G. A. Yanus V. N. Yurova STUDY OF THE EFFECT OF LOMUSTIN ON HER2-POSITIVE BREAST CANCER IN FVB/N HER-2 TRANSGENIC MICE Сибирский онкологический журнал her2-положительный рак молочной железы трансгенные по гену her2 мыши линии fvb/n интракраниальная опухоль ломустин индекс роста опухоли |
| title | STUDY OF THE EFFECT OF LOMUSTIN ON HER2-POSITIVE BREAST CANCER IN FVB/N HER-2 TRANSGENIC MICE |
| title_full | STUDY OF THE EFFECT OF LOMUSTIN ON HER2-POSITIVE BREAST CANCER IN FVB/N HER-2 TRANSGENIC MICE |
| title_fullStr | STUDY OF THE EFFECT OF LOMUSTIN ON HER2-POSITIVE BREAST CANCER IN FVB/N HER-2 TRANSGENIC MICE |
| title_full_unstemmed | STUDY OF THE EFFECT OF LOMUSTIN ON HER2-POSITIVE BREAST CANCER IN FVB/N HER-2 TRANSGENIC MICE |
| title_short | STUDY OF THE EFFECT OF LOMUSTIN ON HER2-POSITIVE BREAST CANCER IN FVB/N HER-2 TRANSGENIC MICE |
| title_sort | study of the effect of lomustin on her2 positive breast cancer in fvb n her 2 transgenic mice |
| topic | her2-положительный рак молочной железы трансгенные по гену her2 мыши линии fvb/n интракраниальная опухоль ломустин индекс роста опухоли |
| url | https://www.siboncoj.ru/jour/article/view/1188 |
| work_keys_str_mv | AT anstukov studyoftheeffectoflomustinonher2positivebreastcancerinfvbnher2transgenicmice AT sfvershinina studyoftheeffectoflomustinonher2positivebreastcancerinfvbnher2transgenicmice AT nakoziavin studyoftheeffectoflomustinonher2positivebreastcancerinfvbnher2transgenicmice AT tyusemiglazova studyoftheeffectoflomustinonher2positivebreastcancerinfvbnher2transgenicmice AT lvfilatova studyoftheeffectoflomustinonher2positivebreastcancerinfvbnher2transgenicmice AT dkhlatipova studyoftheeffectoflomustinonher2positivebreastcancerinfvbnher2transgenicmice AT aoivantsov studyoftheeffectoflomustinonher2positivebreastcancerinfvbnher2transgenicmice AT vgbespalov studyoftheeffectoflomustinonher2positivebreastcancerinfvbnher2transgenicmice AT alsemenov studyoftheeffectoflomustinonher2positivebreastcancerinfvbnher2transgenicmice AT oabelyaeva studyoftheeffectoflomustinonher2positivebreastcancerinfvbnher2transgenicmice AT gskireeva studyoftheeffectoflomustinonher2positivebreastcancerinfvbnher2transgenicmice AT vaalexandrov studyoftheeffectoflomustinonher2positivebreastcancerinfvbnher2transgenicmice AT gvtochilnikov studyoftheeffectoflomustinonher2positivebreastcancerinfvbnher2transgenicmice AT invasilyeva studyoftheeffectoflomustinonher2positivebreastcancerinfvbnher2transgenicmice AT mamaydin studyoftheeffectoflomustinonher2positivebreastcancerinfvbnher2transgenicmice AT mltyndyk studyoftheeffectoflomustinonher2positivebreastcancerinfvbnher2transgenicmice AT sskruglov studyoftheeffectoflomustinonher2positivebreastcancerinfvbnher2transgenicmice AT gayanus studyoftheeffectoflomustinonher2positivebreastcancerinfvbnher2transgenicmice AT vnyurova studyoftheeffectoflomustinonher2positivebreastcancerinfvbnher2transgenicmice |